NEWS
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Kintara Therapeutics (Nasdaq: KTRA) provided updates on its corporate developments and REM-001 clinical study. Key points include:
1. Merger agreement with TuHURA Biosciences, with Kintara stockholders owning 5.45% of the combined company.
2. Special Meeting of Stockholders on September 20, 2024, to approve the merger.
3. REM-001 study for cutaneous metastatic breast cancer (CMBC) has enrolled 4 out of 10 required patients.
4. No treatment-related safety issues identified in the REM-001 study to date.
5. $2.0 million SBIR grant covering majority of REM-001 study costs.
6. Kintara may face financial difficulties without the merger completion.
Kintara Therapeutics (Nasdaq: KTRA) provided updates on its corporate developments and REM-001 clinical study. Key points include:
1. Merger agreement with TuHURA Biosciences, with Kintara stockholders owning 5.45% of the combined company.
2. Special Meeting of Stockholders on September 20, 2024, to approve the merger.
3. REM-001 study for cutaneous metastatic breast cancer (CMBC) has enrolled 4 out of 10 required patients.
4. No treatment-related safety issues identified in the REM-001 study to date.
5. $2.0 million SBIR grant covering majority of REM-001 study costs.
6. Kintara may face financial difficulties without the merger completion.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1399Followers
79Following
10KVisitors
Follow